Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease

This study has been terminated.
Information provided by (Responsible Party):
Baxalta US Inc. Identifier:
First received: October 29, 2013
Last updated: August 7, 2015
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)